Ohhara K, Kubota H, Hashiba H, Kohchi T, Urushibara T, Kikuchi N, Yotsumoto T, Itoh K, Ichimura K, Uchida T, Kobayashi A, Kanno H, Kikuchi N
Jpn J Antibiot. 1979 May;32(5):631-7.
The clinical effects of PC-904, a new semisynthetic penicillin, were studied in patients with biliary tract diseases, and the results were as follows: 1) PC-904 showed an average peak serum level of 40.7 +/- 11.6 microgram/ml 2 hours after an intravenous drip infusion of 1 g of the agent. The biliary level showed a peak value of 126.5 +/- 85.4 microgram/ml 2 hours to 3 hours after the infusion. 2) Isolated organisms from bile before the treatment were E. coli, Klebsiella, Proteus, Pseudomonas, Enterococcus and Bacteroides. MIC of PC-904 on 18 strains of isolated organisms was almost 6.25 microgram/ml or less. All isolated organisms except one strain of Klebsiella oxytoca disappeared after the treatment. 3) Six patients with cholelithiasis were medicated with PC-904 to prevent post-operative infections. The clinical effects were good in 4, poor in 1 and unknown in 1 case. 4) As to side effects no adverse reactions and allergic reactions were noted. Also no significant abnormalities of laboratory findings were observed.
对新型半合成青霉素PC - 904在胆道疾病患者中的临床效果进行了研究，结果如下：1）静脉滴注1g该药物后2小时，PC - 904的血清平均峰值水平为40.7±11.6微克/毫升。输注后2至3小时，胆汁水平出现峰值，为126.5±85.4微克/毫升。2）治疗前从胆汁中分离出的 organisms 有大肠杆菌、克雷伯菌、变形杆菌、假单胞菌、肠球菌和拟杆菌。PC - 904对18株分离出的 organisms 的最低抑菌浓度几乎为6.25微克/毫升或更低。除一株产酸克雷伯菌外，所有分离出的 organisms 在治疗后均消失。3）6例胆石症患者接受PC - 904治疗以预防术后感染。4例临床效果良好，1例效果不佳，1例情况不明。4）关于副作用，未观察到不良反应和过敏反应。实验室检查结果也未发现明显异常。 （注：原文中“organisms”未明确具体中文，可根据上下文灵活翻译，比如“细菌”等，这里保留英文以便准确呈现原文结构）
